Bikes line up for Originals Ashburton motorcycle show
Willie Little and his one-of-a-kind 1996 Harley Davidson sporty chopper. PHOTO: TONI WILLIAMS
Willie Little took a 1996 Harley-Davidson Sportster and blinged it up with chrome.
It has a six inch oversized springer front end, been lowered an inch at the back and a customised sissy bar.
It is one of the toys, he said. Little, an engineer, did the work himself during Covid lockdown.
He bought the 1200cc sportster in 2019 for $5000 and imported parts from the United States.
Then Covid hit, giving him time to work on his machine.
About 40 motorbikes were on show at the recent Originals Ashburton motorcycle show and shine in the Ashburton RSA. Photo: Supplied
He stripped it all back and replaced the front, lowered it at the rear and handcrafted his own sissy bar.
Replaced the belt with a chain, put in a new exhaust, custom chromes and paint work.
Then he added a small 1950s-style peanut tank which holds about 3.5 litres of fuel.
"Enough to get you to the pub and back," he said.
The motorbike was on show at the recent Originals Ashburton motorcycle show and shine at the Ashburton RSA.
Photo: Supplied
There were about 40 bikes of all makes and models inside and outside the event ranging in ages from 1953 to 2025.
Little finally finished the motorcycle in time for last year's annual November bike show.
In keeping with his Harley-Davidson preference, his next project is to rebuild a Pan America.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
MedX Announces Final Closing of Non-Brokered Private Placement
MISSISSAUGA, Ontario, June 09, 2025--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory "hold" period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ("Unit"). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant ("Warrant(s)"), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants ("Agent's Warrant(s)") (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant ("Agent's Share Purchase Warrant"), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. View source version on Contacts MedX Health Druhan, President, Dermatological (+1) 905-599-7852
Yahoo
20 minutes ago
- Yahoo
Ispire Malaysia Reaffirms Full Regulatory Compliance and Export-Only Manufacturing Operations
LOS ANGELES, June 9, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that its Malaysian subsidiary, Ispire Malaysia Sdn Bhd ("Ispire Malaysia"), reaffirmed its strict compliance with all applicable Malaysian laws and regulations. This clarification follows recent media reports and public interest concerning the Company's manufacturing activities in Malaysia. Ispire Malaysia confirms that all manufacturing activities at its facility in Johor are exclusively for export purposes and do not involve the production or distribution of any nicotine- or cannabis-containing liquids or gels within Malaysia and for export. "Ispire Malaysia operates under stringent procedures to ensure all manufacturing is 100% export-oriented," said Michael Wang, Co-CEO of Ispire Technology Inc. "We believe our operations fully comply with Malaysian law, and we are committed to transparency and regulatory cooperation at both federal and state levels." Key Clarifications: No Local Distribution: All products manufactured in Malaysia are not sold, distributed, or marketed in the Malaysian market. No Nicotine or Cannabis Content: The facility produces semi-finished vaporizer hardware only, with no liquids or gels involved at any point in production. No Medical Devices Manufactured: While the facility is capable of producing certified components, no medical devices are currently manufactured. Any future activity in this sector would follow a comprehensive regulatory review. Advanced Safety Features: Ispire products will integrate blockchain-based age-gating and geo-fencing technology, ensuring use is restricted to adults and compliant areas. The company's patented technology has been submitted for review by the U.S. Food and Drug Administration. The Company also noted that recent commentary referencing cannabis-related products was based on marketing materials related to Ispire's U.S. operations, which operate in jurisdictions where such products are legal. These materials do not reflect the nature of the Company's business conducted in Malaysia. With an investment target exceeding USD 50 million, Ispire Malaysia has positioned itself as a premier manufacturing hub in Southeast Asia, supporting job creation and technological innovation aligned with Malaysia's industrial development goals. "We remain committed to upholding the highest standards of compliance, safety, and corporate responsibility," said Wang. For further information, please visit About Ispire Technology is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit or follow Ispire on Instagram, LinkedIn, Twitter and YouTube. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company meeting its investment target in Malaysia as currently planned, to a lesser degree, or at all; the Company's continued compliance with applicable laws and regulations in the jurisdictions in which it operates; the approval or rejection of any PMTA submitted by the Company; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals regarding age-gating technology, or otherwise, as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's business strategies; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2024 and any subsequent filings which Ispire makes with the SEC, including the Ispire's Quarterly Report on Form 10-Q for the period ended March 31, 2025. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect. IR Contacts:For more information, kindly contact:Investor RelationsSherry Zheng718.213.7386ir@ Strategic CommunicationsPhil Carlson212.896.1233ispire@ Contact:Ellen Mellody570.209.2947ispire@ View original content: SOURCE Ispire Technology Inc.
Rhyl Journal
20 minutes ago
- Rhyl Journal
Psychological support system opens to infected blood victims
The nationwide service began a phased rollout in September, and is now open to people infected and affected across the country. The Infected Blood Psychological Service will include talking therapies; peer support and psychosocial support, NHS England said. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result, while survivors are living with lifelong health implications. The new service is open to victims of the scandal as well as bereaved partners, parents, children and their extended families. People can self refer by phone or can be referred to the service by their GP. Officials said that a specialist therapist will help create tailored mental health plans for those in need of support. The Infected Blood Inquiry Report is now published on the Inquiry website. Access the Report here: — Infected Blood Inquiry (@bloodinquiry) May 20, 2024 Claire Murdoch, national mental health director at NHS England, said: 'The contaminated blood scandal and the subsequent long fight for answers have had life-altering physical and psychological impacts for thousands across the country and the NHS is determined to ensure that anyone infected or affected can receive evidence-based support and treatment. 'It has been so important that the Infected Blood Psychological Service has been co-designed with members of the infected blood community to ensure the best and most personalised care possible, and we are very grateful to all our partners who have helped establish these vital new services.' Nicola Leahey, from Lancashire, was infected with Hepatitis C following blood transfusions in 1975 and/or 1980, and was part of the expert advisory group to the new service. 'After my diagnosis, I felt that my body had been violated, that I had been physically and mentally abused, stripped of my dignity, my self-esteem diminished, I mourned lost opportunities, I felt betrayed,' she said. 'So many of us have long awaited the opportunity to have professional support to try to cope with the trauma and life-long effects that we've been subjected to. 'I'm thrilled that this much-needed service is now operational for both those infected and affected members of the infected blood community across England.' Professor Meghana Pandit, co-national medical director for secondary care at NHS England, added: 'Following the recommendations of the Inquiry, this new service represents a vital step in ensuring patients and families affected in England can be offered tailored psychological treatment and support, and we are pleased that specialist clinics are now open in all areas of England. 'This bespoke psychological treatment is already making a difference to the lives of the first people to access it, and we now want to ensure everyone eligible is aware of the services provided.'
